Authors
Latest:
Dr Somaiah on the Peak Trial in GISTNeeta Somaiah, MD, discusses enrollment criteria for the phase 3 Peak trial in patients with gastrointestinal stromal tumor and the advantages of this trial’s design.
Latest:
Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCCNeil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab in the treatment of patients with cutaneous squamous cell carcinoma.
Latest:
Dr. Dunavin on Ongoing Research for Myelofibrosis TreatmentsNeil Dunavin, MD, MS, discusses ongoing research on therapies for patients with myelofibrosis.
Latest:
Dr. Kay Discusses Combination Strategies in CLLNeil E. Kay, MD, professor of medicine, Mayo Clinic, discusses combination strategies for patients with chronic lymphocytic leukemia (CLL).
Latest:
Dr. Horowitz on Frontline Strategies in Newly Diagnosed Ovarian CancerNeil Horowitz, MD, director of Clinical Research in Gynecologic Oncology, assistant professor of Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School, Dana-Farber Cancer Institute, discusses frontline strategies in the treatment of patients with newly diagnosed advanced ovarian cancer.
Latest:
Dr. Berinstein on Combination Treatments for High-Risk and Recurrent Follicular LymphomaNeil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.
Latest:
Dr. Spector Discusses Breast Cancer HeterogeneityDr. Neil Spector, from Duke Cancer Institute, Explains Breast Cancer Heterogeneity
Latest:
Dr. Shah on TKI Treatment Discontinuation in CMLNeil P. Shah, MD, PhD, professor of medicine, Division of Hematology and Oncology, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses TKI treatment discontinuation in patients with chronic myeloid leukemia.
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician FactorsFor a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Latest:
Dr Shah on Remaining Unmet Needs in RCC After Frontline IO CombinationsNeil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician FactorsFor a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Latest:
As Medicare Goes, so Goes Managed Care (Or so the Saying Goes)Who will lead the way in promoting greater adoption of e-prescribing, and how can physicians get the most out of using this technology in their practice?
Latest:
Dr. Chao on Minimal Residual Disease in ALLNelson Jen An Chao, MD, professor of medicine, Donald D. and Elizabeth G. Cooke Cancer Research Professor, chief, Division of Cell Therapy in the Department of Medicine, Duke Cancer Institute, discusses minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL).
Latest:
Dr. Butowski on Real-Time Imaging of Nanoliposomal Irinotecan InjectionNicholas A. Butowski, MD, discusses an early-stage study of convection-enhanced delivery of nanoliposomal irinotecan with real-time imaging.
Latest:
Where Sipuleucel-T Fits in the Treatment of mCRPCSipuleucel-T received an FDA approval in 2010 and a subsequent CMS coverage decision in 2011. At Lancaster Urology in Pennsylvania, we began infusing sipuleucel-T in 2011, and at the 7-year mark, we conducted a review to evaluate these first years of therapy.
Latest:
Dr. Butowski Discusses Dianhydrogalactitol in Patients with Recurrent GBMNicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I/II study of dianhydrogalacitol in patients with recurrent glioblastoma multiforme (GBM).
Latest:
Dr Rohs on Pityriasis Rubra Pilaris as an Early Signal of Lung Cancer RecurrenceNicholas C. Rohs, MD, discusses a case study that he presented during the Interesting Cases session at the 18th Annual New York Lung Cancers Symposium®.
Latest:
Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCCNicholas G. Cost, MD, assistant professor, Surgery-Urology, Department of Pediatric Urology/ Urologic Oncology, University of Colorado Denver, discusses a clinical trial exploring pembrolizumab (Keytruda) plus axitinib (Inlyta) in patients with renal cell carcinoma (RCC).
Latest:
Expanding Opportunities for Real-World Evidence in OncologyReal-world evidence is finding an expanded role in oncology, prompting experts to rethink how data are gathered on the day-to-day usefulness of drugs for regulatory decisions.
Latest:
Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin CraneOncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.
Latest:
Dr McAndrew on a Subgroup Analysis of NATALEE in HR+/HER2– Early Breast CancerNicholas P. McAndrew, MD, MSCE, discusses a subgroup analysis of the NATALEE trial in HR+/HER2– early breast cancer by prior systemic treatment.
Latest:
Dr. Turner Discusses the PALOMA-3 TrialNicholas Turner, PhD, discusses the PALOMA-3 trial, which studied palbociclib combined with fulvestrant for the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer after endocrine failure.
Latest:
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and ObservationThe smoldering multiple myeloma treatment paradigm harbors fractures in the consensus regarding the optimal management of this disease, with some experts favoring a watch-and-wait approach and others advocating for early treatment.
Latest:
Dr. Grupka on Mutations in Patients With Myelodysplastic SyndromeNichon L. Grupka, MD, pathologist, Novant Health Thomasville Medical Center, discusses the manifestations of mutations in myelodysplastic syndrome (MDS).
